IsraelLawThe decision to establish an Israeli R&D center is rarely made on legal grounds first. Companies come to Israel for the talent: a country with roughly 9.6 million people producing more engineers per capita than almost anywhere in the world, with deep specialisms in cybersecurity, semiconductor design, autonomous systems, medical devices, and AI. Legal and tax structure decisions follow.
But the legal framework is consequential. Get the entity structure wrong and you create permanent establishment risk for the parent. Get the IP ownership provisions wrong and the technology developed in Israel belongs to the Israeli employees or gets locked up by IIA grant restrictions. Get the transfer pricing wrong and face a seven-year retroactive assessment from the ITA. This guide covers entity structure, IP ownership, transfer pricing, and employment law, with specific reference to Israeli legislation, the November 2025 ITA circular, and the IIA's current programs.
1. Why Multinationals Choose Israel for R&D
IIA grant funding reduces cost. The Israel Innovation Authority, operating under the Encouragement of Industrial Research, Development and Technological Innovation Law 5744-1984, funds a significant portion of approved R&D costs in Israel — with the explicit goal of anchoring technology development in Israel. For multinational programs approved under the IIA's MNC collaboration track, grant rates of 30–50% of approved expenses are available. The cost offset is real; the legal strings attached to it (principally Section 19B) are also real and require active management.
Section 102 stock options reduce compensation cost. Under Section 102 of the Income Tax Ordinance, employee stock options deposited with an ITA-approved trustee for 24 months are taxed at a flat 25% capital gains rate when the employee eventually sells. The alternative — paying cash compensation at marginal income tax rates of up to 47% — is far more expensive for both the employee and the employer. This makes equity-heavy compensation packages viable in Israel in a way they are in very few other jurisdictions, and it drives the structure of employment agreements for R&D center staff.
The Preferred Technological Enterprise (PTE) regime cuts corporate tax. An Israeli subsidiary qualifying as a Preferred Technological Enterprise under the Encouragement of Capital Investments Law 5719-1959 pays corporate tax at 12% (7.5% in designated development zones) rather than the standard 23%. The PTE qualification requires an IIA certificate confirming the company's R&D character. Most genuine R&D subsidiaries qualify.
2. Subsidiary vs. Branch: Why Almost Everyone Chooses a Subsidiary
A foreign company considering Israel for R&D operations has two structural options: register an Israeli subsidiary (a separate legal entity) under Sections 2–30 of the Companies Law 5759-1999, or register a branch (*sviv chutz*) of the foreign company under Sections 346–364 of the same law.
In practice, over 95% of multinational R&D operations in Israel use a wholly-owned subsidiary, not a branch. The reasons:
- Liability separation: The subsidiary is a distinct legal person. Claims against the Israeli operations — employee disputes, contractor claims, NII assessments — stop at the subsidiary level and do not reach the parent's global balance sheet
- IIA grant eligibility: IIA grants under the R&D Law are awarded to Israeli legal entities. A foreign branch is technically eligible, but the administrative burden and the absence of a clean Israeli corporate identity creates practical difficulties in the grant application process. An Israeli subsidiary has a company number, a tax file number, and a straightforward corporate identity that IIA processes smoothly
- Section 102 stock option trust structure: Section 102 of the Income Tax Ordinance requires the granting company to be an Israeli company for the capital gains track to apply. A branch cannot be a Section 102 granting company; a subsidiary can
- Preferred Technological Enterprise qualification: The PTE regime requires an Israeli tax resident company. A branch of a foreign company is taxed in Israel only on its Israeli-source profits, but the PTE rate reduction is available only to Israeli resident companies — which a branch is not
- Permanent establishment management: Paradoxically, a properly structured subsidiary reduces PE risk for the parent. The subsidiary is a separate entity; its activities in Israel are its own, not the parent's. As long as the subsidiary is genuinely independent — its own management, its own contracts, arm's length transfer pricing — the parent's global profits are not exposed to Israeli tax. A branch, by definition, is not a separate entity; it is the foreign company operating in Israel, which by itself constitutes a PE
Registration of an Israeli private subsidiary costs NIS 2,611 at the Companies Registrar and takes 3 to 7 business days. The more time-consuming step is opening the subsidiary's Israeli bank account — due to AML and KYC requirements for foreign-owned entities under the Prohibition on Money Laundering Law 5760-2000, expect 8 to 16 weeks from company registration to an operational bank account.
In Practice: The only scenario where a branch genuinely makes sense for an R&D operation is a short-duration project — one to two years — where the parent wants to avoid the overhead of a separate legal entity and has no interest in IIA grants, PTE qualification, or Section 102 stock option grants. In that case, the branch must still register with the ITA (Section 350 of the Companies Law requires a branch to file with the Registrar within one month of commencing operations), maintain its own Israeli bookkeeping, and file annual tax returns in Israel on its Israeli-sourced profits. The administrative savings versus a subsidiary are smaller than they appear.
3. Israel Innovation Authority MNC R&D Collaboration Program
The IIA's Multinational Corporations R&D Collaboration Program (*Tochnit Shituph B'Pituach Ve'Hatzmaha Im Chevrot Multinatzionaliot*) is designed specifically for foreign companies that want to fund R&D projects in Israel jointly with an Israeli company or institute. It is not the same as the IIA's general startup grant tracks, which target Israeli companies independently.
Under the MNC program, a multinational submits an application proposing an R&D project to be conducted by its Israeli subsidiary or an Israeli partner company, with the multinational as the primary funder. The IIA co-funds the approved portion — typically 30–50% of the approved R&D budget — as a grant to the Israeli entity conducting the work. The multinational receives the benefit of Israeli R&D at reduced cost; the IIA retains the standard Section 19B restrictions on transferring the technology outside Israel.
Key eligibility requirements for the MNC program as of the 2025-2026 call for proposals:
- The Israeli participant must be an Israeli registered company or academic/research institute
- The multinational parent must be a company with global revenues demonstrating capacity to fund the project
- The proposed project must constitute genuine R&D activity — not routine engineering, technical support, or product customization
- The project must result in new knowledge, technology, or IP with commercial potential
- The multinational must commit to a minimum two-year engagement in Israel following the project
Grant amounts under the MNC program typically range from NIS 500,000 to NIS 5,000,000 per approved project, depending on the budget and the strategic priority level the IIA assigns to the technology area. Applications are reviewed on a rolling basis, but the IIA's main calls for international R&D collaboration open in spring and autumn each year.
In Practice: The MNC grant process takes 6 to 9 months from initial application to a signed grant agreement. Foreign companies that plan their Israeli R&D center launch without accounting for this timeline either miss the first grant cycle entirely or start incurring costs before the grant is approved (which still counts toward approved expenditures as long as the project was pre-notified to the IIA). The IIA has a dedicated MNC track team that responds to pre-application consultations — a 30-minute call with the IIA's investment promotion unit before filing formally saves significant time in structuring the application to fit their criteria. The IIA's investment promotion contact for MNCs is published on the innovationisrael.org.il site under "International R&D Programs."
4. Transfer Pricing: The November 2025 ITA Circular on R&D Centers
The Israel Tax Authority released a finalized Transfer Pricing Circular on November 2, 2025 (*Chozer Mas Hakhnasah 17/2025*). It establishes the ITA's binding approach to reviewing transfer pricing arrangements between Israeli R&D subsidiaries and their foreign parent companies — historically the most common audit trigger for multinational R&D operations in Israel.
The cost-plus model. The standard arrangement for a captive R&D center is a cost-plus service agreement: the Israeli subsidiary performs R&D work as a "contract researcher" for the parent, and is compensated at its total costs plus a defined mark-up (the "plus"). The parent owns all IP developed. The Israeli subsidiary takes no market risk, no IP ownership risk, and earns a routine contractor return. Transfer pricing law requires this return to be consistent with what an independent arm's-length contractor would earn for comparable services.
The November 2025 circular addresses the long-running dispute between the ITA and multinationals over whether Israeli R&D centers — which the ITA frequently argued were more than routine contractors — should receive higher returns reflecting the value of the Israeli employees' innovation. The circular establishes:
- The qualifying R&D center definition: An Israeli entity qualifies as a routine R&D center (and thus the cost-plus model applies without challenge) when: the foreign parent has global revenues over NIS 10 billion; the parent is resident in a country with a tax treaty or information exchange agreement with Israel; Israeli tax residents hold no more than 10% of the parent's voting rights; and the Israeli entity's sole activity is contract R&D services for the foreign group, conducted under the group's direction and at the group's IP risk
- The ITA audit restriction: Where an Israeli entity meets these conditions, the ITA's field audit team may only challenge the cost-plus mark-up if the challenge has prior approval from the ITA's dedicated transfer pricing technical team. This significantly limits opportunistic audit challenges based on the auditing officer's own view of what the center is worth
- The acceptable mark-up range: The circular indicates that cost-plus mark-ups of 5–12% are presumptively acceptable for qualifying routine R&D centers, without requiring the taxpayer to produce a full benchmarking study for each year. Mark-ups outside this range require benchmarking documentation
Multinationals whose Israeli subsidiaries do not meet the qualifying criteria — because the parent is smaller, because Israeli residents hold more than 10% of the parent, or because the Israeli center has entrepreneurial risk or partial IP ownership — remain subject to full transfer pricing analysis under the Income Tax Regulations (Determination of Market Conditions) 5766-2006.
In Practice: The November 2025 circular resolves a conflict that had been generating ITA assessments for over a decade. Prior to it, ITA field auditors routinely assessed Israeli R&D subsidiaries on the theory that their talented employees were worth more than a routine cost-plus return — effectively arguing for a higher taxable profit in Israel. For a qualifying entity under the circular's criteria, the 5–12% mark-up range provides certainty without annual benchmarking costs (which run NIS 50,000–150,000 per year for a full study). The practical action item: review your intercompany service agreement to confirm it documents the qualifying criteria, price the mark-up within the acceptable range, and maintain annual documentation showing the activities qualify as contract R&D rather than autonomous development.
5. IP Ownership and the Section 19B Restriction
IP ownership is the central legal tension in every Israeli R&D center: the parent company wants to own all technology developed in Israel; Israeli law creates two mechanisms that can complicate that goal.
Employee inventions default to the employer. Under Section 132 of the Patents Law 5727-1967, inventions made by an Israeli employee in the scope of their employment belong to the employer without any need for a specific IP assignment clause. The employment agreement does not need to say "all IP is assigned to the company" — the statute assigns it. However, Section 134 of the same law gives employees the right to "adequate remuneration" for service inventions that generate exceptional commercial value. In practice, the ITA's standard approach is to address this through the Section 102 stock option program rather than inventor bonuses, and that is the model followed by most multinational R&D centers.
Section 19B applies to IIA-funded technology. If the Israeli subsidiary receives IIA grants, Section 19B of the R&D Law prohibits transferring the know-how developed with grant funding outside Israel without prior IIA approval. "Transfer" is broadly interpreted to include: outright IP assignments to the parent; exclusive licences to the parent; and, in some cases, M&A transactions where effective control of the technology moves outside Israel. The restriction does not prohibit the parent from using the technology — it prohibits the technology itself from being relocated outside Israel in a way that removes it from the IIA's supervision.
The IIA's approval process for technology transfers typically takes 60 to 120 days and results in one of three outcomes: approval without conditions; approval with a royalty obligation running to 150–300% of the original grant; or refusal (rare, but possible for sensitive technologies). The royalty obligation, if imposed, is calculated on worldwide revenues from products incorporating the funded technology — which for a commercially successful technology can represent a very large absolute sum.
For multinationals operating on a pure cost-plus contract R&D model — where the parent owns all IP from the moment it is created, and the Israeli subsidiary is merely performing services — Section 19B applies to the Israeli entity's operations, but the IP never technically "moves" from Israel to the parent because the parent owned it all along. In this model, the IIA grant restricts where the R&D work can be done, not where the IP is registered or used. Confirm this interpretation with the IIA in writing before closing any grant agreement, because oral assurances are not binding on a future IIA administration.
In Practice: The most expensive Section 19B situations arise not from ongoing operations but from M&A. A foreign company acquiring an Israeli tech company with a grant history often discovers the Section 19B restriction only during due diligence, a few weeks before the planned closing. IIA approval for the acquisition then takes 60–120 days, delaying or restructuring the deal. Section 19B approval for an acquisition can also include a royalty commitment — on revenues from technology the acquirer just paid full market value for. For any acquisition of an Israeli company that has received more than NIS 1,000,000 in total IIA grants, Section 19B diligence is non-negotiable and must be completed before signing, not after.
6. Employment Law for Israeli R&D Center Staff
An Israeli R&D subsidiary is an Israeli employer, fully subject to Israeli labor law. Multinationals that assume they can apply their standard global HR playbook to Israeli employees consistently run into problems. Israeli labor law is mandatory and protective, and very little of it can be contracted out of.
Key employment law obligations for an Israeli R&D center:
Written employment agreements. Every employee must have a written employment agreement in Hebrew (or bilingual). Under the Employment (Equal Opportunities) Law 5748-1988, employment agreements for senior technical employees must specify the employee's role, compensation, and at least the main terms of any benefit entitlements. There is no prescribed form, but the Ministry of Labor enforces this requirement at the time of any labor dispute.
Mandatory pension contributions. From the first month of employment, Israeli employers must contribute to a pension fund (*keren pensia*) at a total rate of approximately 21.33% of salary: 6.5% employee contribution, 6.5% employer contribution, and 8.33% employer severance component. The September 2008 General Collective Agreement and subsequent Expansion Orders make this mandatory for all employees in Israel regardless of employment contract terms or the employee's own preferences.
Section 14 election for severance. Under Section 14 of the Severance Pay Law 5723-1963, employers who consistently contribute the full 8.33% to a pension fund with a proper Section 14 letter of undertaking release themselves from separate severance liability when the employee leaves. Without a valid Section 14 election, severance accrues at one month per year of service and must be paid from company funds on top of the pension contribution. Most Israeli R&D centers set up the Section 14 arrangement from day one; retroactively applying it to long-tenured employees is complex.
Advance notice and pre-dismissal hearing. Israeli employees cannot be dismissed without a formal pre-dismissal hearing (*shmiath tviunot*) — a procedural requirement created by the National Labor Court that applies regardless of what the employment contract says. Notice periods range from 1 day (in the first month) to 1 month (after one year) under the Notice Period Law 5761-2001, with contractual extensions common for senior technical roles.
NII employer contributions. The Israeli R&D subsidiary must register with the National Insurance Institute (NII / *Bituach Leumi*) as an employer and pay contributions on all wages. In 2026, the employer rate is 3.55% on income below NIS 7,522 per month and 7.6% above it. NII contributions entitle Israeli employees to health insurance through the public health fund enrollment, maternity pay, disability, and unemployment benefits.
In Practice: The most consistent employment law failure in multinational R&D centers is inadequate documentation of the pre-dismissal hearing when a senior technical employee's role is eliminated in a global restructuring. The global HR process for a role elimination — a notification call, a severance offer, and departure by end of day — does not meet the Israeli pre-dismissal hearing standard. Under Israeli National Labor Court precedent, the hearing must be genuine: the employee must be told the reason for the proposed dismissal, given a real opportunity to respond, and the employer must consider the response before making a final decision. Conducting this process through an Israeli employment lawyer, even for employees the company regards as straightforward exits, prevents Regional Labor Court claims that typically add 2–6 months' salary to the termination cost.
7. Tax Incentives for Israeli R&D Centers
The three main regimes — PTE corporate tax, Section 102 stock options, and the *keren hishtalmut* — work together, and most R&D centers should structure to use all three from day one rather than adding them retroactively.
Preferred Technological Enterprise (PTE). Under Amendment 73 to the Encouragement of Capital Investments Law, an Israeli company whose R&D expenditures account for 7% or more of its revenues (or NIS 75 million in absolute terms) and which holds or develops qualifying intellectual property may apply to the Israel Investment Authority for PTE status. A qualifying PTE pays corporate tax at 12% nationally (7.5% in the Negev and Galilee Priority Areas) rather than the standard 23%. Dividends distributed by a PTE to a foreign parent are subject to 4–20% withholding depending on where the parent is resident. For a 100-person R&D center generating NIS 80 million in annual revenue, the difference between 23% and 12% corporate tax on NIS 10 million of taxable profit is NIS 1,100,000 per year. PTE status must be applied for proactively and re-confirmed when the company's profile changes substantially.
Section 102 stock options. As noted, Israeli employees receiving equity grants under a properly structured Section 102 capital gains track plan pay 25% flat tax on their gain rather than marginal income tax rates of up to 47%. The employer also benefits: Section 102 grants do not generate employer NII liability at grant or vesting, only at exercise. For a 50-person technical team receiving average grants of NIS 500,000 per person over a 4-year vesting schedule, the NII and income tax differential versus a cash-equivalent compensation package is material. A Section 102 plan requires a trust deed, ITA registration of the trust, and careful plan documentation — but this is standard practice for Israeli R&D centers and any competent Israeli corporate lawyer can set it up in two to four weeks.
Keren Hishtalmut (Training Fund). Israeli employers can contribute up to 7.5% of an employee's salary (with the employee contributing 2.5%) to a *keren hishtalmut* — a tax-advantaged savings fund that invests in capital markets. After six years of contributions, the fund's balance and growth are tax-free on withdrawal. For highly paid engineers, the keren hishtalmut is one of the most tax-efficient elements of the total compensation package, and it is expected by any experienced Israeli technology professional. The 2026 tax-exempt withdrawal ceiling per individual is approximately NIS 19,800 in annual contributions from the employer side.
In Practice: The PTE regime and Section 102 work together most effectively when the R&D center is structured from the first day with both in mind. PTE requires qualifying R&D expenditures — salaries are the largest component, and Section 102 grant expenses count toward the R&D expenditure calculation. A company that begins as a cost-plus contractor without PTE status and then attempts to qualify retroactively for a year that has already been assessed loses the benefit for that year permanently. The ITA certification process takes 3 to 6 months from application; apply in the first year of operations so that PTE status is in place before the first tax assessment becomes final.